Imugene (ASX: IMU) ropes in US biotech executive as Non-Executive Director

2 min read | June 21, 2023 10:37 AM AEST | By Team Kalkine Media

Google News:

Imugene (ASX: IMU) ropes in US biotech executive as Non-Executive Director — Image source: Company website

Recent News

The Contrarian's Map: Which ASX Sectors Look Cheap Right Now

Buying a Dollar for Seventy Cents: What Does Value Investing Actually...

Growth at What Price? A Sensible Framework for Buying ASX Tech After t...

Best ASX Tech Stocks: Durable Moats After the Shakeout

Make Kalkine Media
My Trusted Source

Highlights

IMU has welcomed Ms Kim Drapkin, a prominent US biotech executive, as Non-Executive Director.

Ms Drapkin has an experience of over 25 years in the pharmaceutical and biotechnology space.

She has extensive knowledge of the US mid-cap biotechnology ecosystem, says IMU.

She is expected to support IMU in expanding investor footprint and further accelerating its clinical development programs in a financially disciplined manner.

Clinical-stage immuno-oncology company Imugene Limited (ASX: IMU) has strengthened its leadership team with the appointment of Ms Kim Drapkin as a Non-Executive Director.

Ms Drapkin, a prominent US biotech executive, has an experience of over 25 years in the pharmaceutical and biotechnology space. She has a strong background in strategic financial planning, capital raising, and finance.

Image source: IMU website, Data source: IMU update

An insight into Ms Drapkin’s profile

Ms Drapkin contributed immensely to the growth of Jounce Therapeutics, Inc. from 2015 until its acquisition in May this year. As the CFO and Treasurer at Jounce, she worked with the CEO to represent the company in the investment and analyst community. She played an instrumental role in its IPO and listing on the NASDAQ.

Previously, she managed a financial consulting firm. Ms Drapkin served as interim CFO for Warp Drive Bio LLC, Eleven Biotherapeutics, Inc., Edimer Pharmaceuticals, Blueprint Medicines Corporation, and other early-stage biotech companies.

She has also worked with EPIX Pharmaceuticals and Millennium Pharmaceuticals.

Ms. Drapkin served on transaction committees and chaired the audit committee and participated in the governance and compensation committees during her tenure with Proteostasis Therapeutics (NASDAQ:PTI) (2019-2020) and Yumanity Therapeutics (NASDAQ:YMTX) (December 2020-December 2022). At both these companies, she served on the board.

Ms Drapkin currently serves as the audit committee chair and compensation committee member on the board of Acumen Pharmaceuticals (NASDAQ:ABOS).

Meanwhile, the company announced that non-executive director Charles Walker will vacate the role on June 30.

IMU shares were trading at AU$ 0.095 at the time of writing on 21 June 2023.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.